文献速递类风湿关节炎

阿巴西普用于类风湿关节炎高危人群的长期结局(ALTO):随机双盲安慰剂对照试验

Long-term outcomes of abatacept in individuals at risk of developing rheumatoid arthritis (ALTO): a randomised, double-blind, placebo-controlled trial.
PubMed 文献 · Lancet Rheumatol · 2026-01-20

ALTO研究延长随访了APIPPRA试验中143例ACPA阳性关节痛高危个体,评估1年阿巴西普治疗后的长期疗效与安全性。基线广泛自身抗体谱者进展风险最高但对阿巴西普反应更好。

要点

  • 1年阿巴西普治疗可将类风湿关节炎进展延迟至多4年。
  • 基线广泛自身抗体谱者进展风险最高,但对阿巴西普反应更好。
  • 治疗期后两组疾病活动度和患者报告结局无显著差异。

核心结论

  • 在高危人群中,1年阿巴西普治疗可将类风湿关节炎进展延迟长达4年。
  • 进展风险最高的广泛自身抗体谱个体对阿巴西普治疗反应更好。

研究设计与样本

  • ALTO为APIPPRA 2b期随机对照试验的长期随访研究,随访4至8年,参与者和临床评估者保持盲态。
  • APIPPRA招募213例ACPA阳性关节痛个体,随机接受52周每周皮下注射125 mg阿巴西普(n=110)或安慰剂(n=103)。
  • 主要结局为从随机化至至少3个关节临床滑膜炎、符合ACR-EULAR 2010标准类风湿关节炎或首次使用DMARDs的时间,以先发生者为准。

主要发现

  • 从随机化起中位随访55个月(IQR 23-74),主要事件从54例增至119例。
  • 治疗期后两组疾病活动度和患者报告结局评估无显著差异。
  • 阿巴西普组发生18例严重不良事件,安慰剂组13例,均未判定与研究药物相关。

关键数值与推荐

  • 主要结局定义:至少3个关节临床滑膜炎、符合ACR-EULAR 2010标准类风湿关节炎或首次使用DMARDs,以先发生者为准。
  • 主要结局按随机化时自身抗体谱分层分析。

临床怎么用

  • 对于ACPA阳性关节痛的高危个体,可考虑1年阿巴西普治疗以延迟类风湿关节炎进展。
  • 基线自身抗体谱广泛者进展风险最高,但可能从阿巴西普治疗中获益更大。

局限性

  • ALTO仅纳入143例APIPPRA参与者,样本量有限。
  • 组间无关节炎生存差异幅度随时间减小。
  • 随访期间严重不良事件两组间数量接近,均未判定与研究药物相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Clinical trials aimed at preventing rheumatoid arthritis in individuals at risk have had variable results. The long-term outcomes of disease interception, however, are not known. We aimed to examine the long-term effect of therapeutic intervention, with emphasis on efficacy and safety. METHODS: The Arthritis Prevention In the Preclinical Phase of Rheumatoid arthritis with Abatacept (APIPPRA) phase 2b, randomised controlled trial recruited 213 anti-citrullinated protein antibody (ACPA) positive individuals with arthralgia in 28 hospital-based early arthritis clinics in the UK and three in the Netherlands, randomly assigning participants to 52 weekly subcutaneous injections of 125 mg abatacept (n=110) or placebo (n=103), with another 52 weeks of follow-up. The APIPPRA Long-Term Outcome (ALTO) study extended follow-up for between 4 and 8 years and study participants and clinical assessors remained masked to treatment group. The primary outcome was the time from randomisation to development of clinical synovitis in at least three joints, rheumatoid arthritis according to American College of Rheumatology-European Alliance of Associations for Rheumatology 2010 criteria, or first treatment with disease modifying anti-rheumatic drugs, whichever was met first. The primary outcome was also stratified by autoantibody profiles defined at the time of randomisation. People with lived experience of rheumatoid arthritis had input into the APIPPRA study design. The study was registered at ISRCTN (ISRCTN-12680338), and is completed. FINDINGS: Between April 26, 2021, and Jan 31, 2023, 143 APIPPRA study participants enrolled in ALTO: 71 in the abatacept group and 72 in the placebo group (mean age 48·2 years [SD 11·2], 112 [78%] females, 31 [22%] males, 116 [81%] White). Median follow-up time from randomisation was 55 months (IQR 23-74). Primary events increased by 54 to 119. The initial between-group difference in restricted mean arthritis-free survival time observed at 2 years in APIPPRA remained significant at 4 years (4·9 months 95% CI 0·1-9·6; p=0·044), although the magnitude of this difference diminished over time. Assessments of disease activity and patient reported outcomes revealed no significant differences between groups beyond the treatment period. However, although participants with a broad autoantibody profile at baseline were at highest risk of progressing, this subgroup responded better to abatacept. There were 18 serious adverse events in the abatacept group and 13 in the placebo group; none deemed related to study drug. INTERPRETATION: In this at-risk population, 1-year treatment with abatacept delayed progression to rheumatoid arthritis for up to 4 years. Those at highest risk of progression have a broad autoantibody profile but are more responsive to abatacept treatment. FUNDING: Bristol Myers Squibb.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Cope AP, Jasenecova M, Vasconcelos JC, et al. Long-term outcomes of abatacept in individuals at risk of developing rheumatoid arthritis (ALTO): a randomised, double-blind, placebo-controlled trial. Lancet Rheumatol. 2026. PMID: 41576971. doi:10.1016/S2665-9913(25)00371-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。